nuva-8k_20210901.htm
false 0001142596 0001142596 2021-09-01 2021-09-01

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2021

 

NuVasive, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

000-50744

33-0768598

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

 

 

 

7475 Lusk Boulevard, San Diego, California 92121

(Address of principal executive offices) (Zip Code)

 

 

 

(858) 909-1800

(Registrant’s telephone number, including area code)

 

 

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NUVA

The NASDAQ Stock Market LLC

(NASDAQ Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

Item 8.01

Other Events.

 

On September 1, 2021, NuVasive, Inc. (the “Company”) issued a press release (the “Organizational Press Release”) announcing new executive leadership roles. A copy of the Organizational Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In the Organizational Press Release, the Company announced that it was realigning the leadership structure for its commercial, commercial enablement, product marketing, and spine research and development organizations, as well as NuVasive Specialized Orthopedics and NuVasive Clinical Services, effective September 1, 2021. Massimo Calafiore, who currently serves as Executive Vice President, Global Business Units, with responsibility for the Company’s business units, product marketing, and spine research and development functions, has assumed the role of Executive Vice President, Chief Commercial Officer, with responsibility for the Company’s product marketing, commercial, and commercial enablement functions, as well as the Company’s business units. The Company also announced that it created a new Chief Technology Officer role, reporting directly to the Chief Executive Officer, to lead spine research and development. With this new structure, the Company eliminated the role of Executive Vice President, Global Commercial, currently held by Brent Boucher, who will be transitioning out of the organization.

 

Item 9.01

Financial Statements and Exhibits.

 

 

(d)

Exhibits.

 

 

Exhibit No.

Description.

99.1

Press Release issued by NuVasive, Inc. on September 1, 2021

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NUVASIVE, INC.

 

 

 

Date: September 1, 2021

 

/s/ Matthew K. Harbaugh

 

 

Matthew K. Harbaugh

 

 

Executive Vice President and Chief Financial Officer

 

nuva-ex991_6.htm

Exhibit 99.1

 

NEWS RELEASE

 

NuVasive Announces New Executive Leadership Roles

 

-- New roles strengthen innovation and go-to-market execution --

-- Massimo Calafiore appointed Chief Commercial Officer --

-- Ryan Donahoe appointed Chief Technology Officer --

 

SAN DIEGO September 1, 2021 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced new executive leadership roles, strengthening its innovation and go-to-market teams while furthering the Company’s growth. Effective immediately, Massimo Calafiore has been appointed Chief Commercial Officer, and Ryan Donahoe has been appointed Chief Technology Officer, both reporting directly to Chief Executive Officer J. Christopher Barry.

 

“This new structure puts in place leaders who have decades of spine and orthopedics experience to advance our near- and long-term strategy as we continue to globalize and scale our business,” said Mr. Barry. “I am confident Massimo’s and Ryan’s proven track records of building strong, effective teams and their commitment to our vision will help us deliver the strongest innovation pipeline in spine and increase value for our stakeholders.”

 

As Chief Commercial Officer, Massimo Calafiore will oversee the product marketing, commercial, and commercial enablement functions, as well as NuVasive Specialized Orthopedics and NuVasive Clinical Services. Since joining the Company in 2017, Mr. Calafiore has held various leadership roles with increasing levels of responsibility, most recently serving as executive vice president, Global Business Units. Prior to NuVasive, he spent 16 years supporting and leading the U.S. business for Waldemar Link, a leader in the orthopedics and medical device industry.

 

As Chief Technology Officer, Ryan Donahoe will continue to lead spine research and development. During his 15 years at NuVasive, Mr. Donahoe has played an integral role in shaping the Company’s comprehensive, procedurally integrated spine portfolio with more than 20 issued and pending patents. Through his leadership and partnership with surgeons, he has helped develop technologies throughout NuVasive’s anterior, posterior, and cervical procedural offerings, along with the integration of the Pulse platform.

 

In connection with this new leadership structure, Brent Boucher, executive vice president, Global Commercial, will transition from the Company.

 

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,700 employees and operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.


Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange CommissionNuVasive's public filings with the Securities and Exchange Commission are available at www.sec.govNuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

###

 

Investor contact:

Juliet C. Cunningham

NuVasive, Inc.

858-210-2129

investorrelations@nuvasive.com  

 

Media contact:

Amanda Rocha

NuVasive, Inc.

858-882-5062

media@nuvasive.com